Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case?control study
about
Use of organic nitrates and the risk of hip fracture: a population-based case-control study.The osteogenesis-promoting effects of alpha-lipoic acid against glucocorticoid-induced osteoporosis through the NOX4, NF-kappaB, JNK and PI3K/AKT pathways.Calibration of FRAX ® 3.1 to the Dutch population with data on the epidemiology of hip fracturesRisk of fracture and the concomitant use of bisphosphonates with osteoporosis-inducing medications.Dopaminergic drugs and the risk of hip or femur fracture: a population-based case-control studyThe risk of fracture in patients with multiple sclerosis: the UK general practice research databaseCombined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis.Knee arthroplasty and risk of hip fracture: a population-based, case-control studyIncidence of Symptomatic Vertebral Fractures Among Newly Diagnosed Autoimmune Diseases Initiating Glucocorticoid Therapy.Risk of fracture after bariatric surgery in the United Kingdom: population based, retrospective cohort study.Single nucleotide polymorphisms of HSP90AA1 gene influence response of SLE patients to glucocorticoids treatment.The Skeletal Effects of Inhaled Glucocorticoids.Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects.Antipsychotic use and the risk of hip/femur fracture: a population-based case-control studyLong-term therapy in COPD: any evidence of adverse effect on bone?Treatment of Pediatric Acute Graft-versus-Host Disease-Lessons from Primary Immunodeficiency?The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights.Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease.Long-term use of fluticasone propionate/salmeterol fixed-dose combination and incidence of nonvertebral fractures among patients with COPD in the UK General Practice Research Database.[Austrian guidance for the pharmacological treatment of osteoporosis in postmenopausal women--update 2009].Mapping the prescriptiome to fractures in men--a national analysis of prescription history and fracture risk.Primary and secondary prophylaxis to the use of inhaled glucocorticoid in primary health care.Vertebral fractures in patients with chronic obstructive pulmonary disease: the EOLO Study.The ability of H1 or H2 receptor antagonists or their combination in counteracting the glucocorticoid-induced alveolar bone loss in rats.Gastrodin protects MC3T3-E1 osteoblasts from dexamethasone-induced cellular dysfunction and promotes bone formation via induction of the NRF2 signaling pathway.Metabolic Disorders in Chronic Lung Diseases.Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study.Curcumin alleviates glucocorticoid-induced osteoporosis by protecting osteoblasts from apoptosis in vivo and in vitro.Risk of cataract and glaucoma in patients with multiple sclerosis
P2860
Q33786888-F16D3F6F-4999-487F-BBD9-D3792A7BA03BQ33794181-938392E7-C9B0-45B6-AB13-7E3379815A1EQ34084507-38FD26BE-0A10-4CC0-B965-11F3FF005163Q34462037-B32CBD4C-5337-4618-BCB9-BA29552C9E75Q35019586-3834E29F-0A59-4E58-8CF0-F6B6E7AE6DAAQ35347484-52C76D44-78F7-4570-993C-85FAAE0AA7A2Q35557927-297D04ED-7797-4FB5-80E6-0513EBF70318Q35730282-9EEB2CAE-2F8C-4462-A055-DEFD348197A7Q35858075-1381B154-6F04-450D-879B-E7D4F41A6F3AQ36144307-3578D10D-7A95-4720-980F-8D7621B4888BQ36632310-10F7FB98-7CC5-491A-BA00-BD31B779FAAAQ36885279-0C1956E0-562E-4BF4-AC74-2208B582C9EBQ37062092-5A75EA58-F1D3-4AB6-9C63-BB37C7F66424Q37308723-316A5918-14C6-4048-8D9B-75DA6A7FE568Q37408472-1F55C1B4-2DBB-4B42-A96F-7506E599151AQ37712454-A2D7E636-546B-41F2-BC39-047D046880BBQ37732574-ADF7BF5C-0444-48D1-A88F-D83E9830FD0DQ42703436-BDEBB55A-0AFB-4B8F-BF8E-AFC87C661AD6Q42780846-B5F6A396-28E6-4F8F-9AA4-12382DFA72F5Q45988702-EAE4B60A-2747-415D-AB57-A8E0D30F332FQ46438287-589D262F-E53B-4858-BB40-E6D4D7E9192DQ46494043-4EE38450-49FB-4DB6-992A-AC13EC0D467EQ47287505-370EA78A-96A4-4859-A13C-43E8FD7C4F6CQ48026063-73E2BE6E-82D5-483B-A165-8FDD29C03F76Q49379739-3D5B8758-2E23-44CE-85A7-104368642013Q49795481-EB1B8C7D-CA25-458F-B70A-72B31B634C29Q54982067-13CFF200-746C-40E1-9D88-B6E47CEDC4B2Q55037768-A7A137C2-625A-41AB-AF14-3D3484E619F7Q57086709-81A3E96D-277C-489C-AD7E-363C0EEE973B
P2860
Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case?control study
description
im Februar 2007 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 February 2007
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2007
@uk
name
Use of inhaled and oral glucoc ...... ation-based case?control study
@en
Use of inhaled and oral glucoc ...... ation-based case?control study
@nl
type
label
Use of inhaled and oral glucoc ...... ation-based case?control study
@en
Use of inhaled and oral glucoc ...... ation-based case?control study
@nl
prefLabel
Use of inhaled and oral glucoc ...... ation-based case?control study
@en
Use of inhaled and oral glucoc ...... ation-based case?control study
@nl
P2093
P2860
P50
P1476
Use of inhaled and oral glucoc ...... ation-based case-control study
@en
P2093
H G M Leufkens
J W J Lammers
P2860
P304
P356
10.1111/J.1365-2796.2006.01754.X
P407
P577
2007-02-01T00:00:00Z